Int J Arrhythm.  2018 Jun;19(2):82-125. 10.18501/arrhythmia.2018.008.

2018 KHRS Guidelines for Catheter Ablation of Ventricular Arrhythmias: Part 3

• Cho Y
• Kim SH
• Kim YR
• Kim YN
• Kim JY
• Kim TH
• Nam GB
• Roh SY
• Park KM
• Park HS
• Pak HN
• Bae EJ
• Oh S
• Yoon N
• Lee MY
• Cho Y
• Jin ES
• Cha TJ
• Choi JI
• Kim J

• KMID: 2418774
• DOI: http://doi.org/10.18501/arrhythmia.2018.008

Abstract

Treatment of ventricular arrhythmias (VA) usually involves managing the underlying cardiac conditions that cause the arrhythmia. However, managing the underlying disease is often challenging, and catheter ablation, or treatment targeting the VA itself might be required in a few patients. In this article, we explored evidence and recommendations regarding the treatment of VA in patients with structural heart disease focusing on the utilization of catheter ablation in these patients. The administration of optimal medical therapy, insertion of an implantable cardioverter-defibrillator, or resynchronization therapy improves survival in patients with left ventricular dysfunction. The role of catheter ablation in preventing sudden cardiac death remains uncertain in this population. In patients with coronary artery disease, reversing myocardial ischemia via revascularization is important in managing VA. Catheter ablation is recommended in patients with recurrent ventricular tachycardia in a setting of ischemic heart disease. In patients with non-ischemic cardiomyopathies such as dilated cardiomyopathy or hypertrophic cardiomyopathy, catheter ablation may be considered for those presenting with drug-refractory ventricular tachycardia.

MeSH Terms

Arrhythmias, Cardiac*
Cardiomyopathies
Cardiomyopathy, Dilated
Cardiomyopathy, Hypertrophic
Catheter Ablation*
Catheters*
Coronary Artery Disease
Death, Sudden, Cardiac
Defibrillators, Implantable
Heart Diseases
Humans
Myocardial Ischemia
Tachycardia, Ventricular
Ventricular Dysfunction, Left